{"id":742248,"date":"2012-02-15T07:00:00","date_gmt":"2012-02-15T07:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-establishes-joint-venture-with-supera-farma-to-commercialize-innovative-pharmaceutical-products-and-branded-generics-in-brazil\/"},"modified":"2023-03-22T00:04:25","modified_gmt":"2023-03-22T04:04:25","slug":"merck-establishes-joint-venture-with-supera-farma-to-commercialize-innovative-pharmaceutical-products-and-branded-generics-in-brazil","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-establishes-joint-venture-with-supera-farma-to-commercialize-innovative-pharmaceutical-products-and-branded-generics-in-brazil\/","title":{"rendered":"Merck Establishes Joint Venture with Supera Farma to Commercialize Innovative Pharmaceutical Products and Branded Generics in Brazil"},"content":{"rendered":"<p class=\"bwalignc\">       New Brazilian Joint Venture to Combine Local and Global Commercial        Expertise     <\/p>\n<p>\n      Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced the formation of a new joint venture (JV) with Supera<br \/>\n      Farma Laboratorios S.A., a Brazilian pharmaceutical company co-owned by<br \/>\n      Crist\u00e1lia and Eurofarma. The new JV will market, distribute and sell a<br \/>\n      portfolio of innovative pharmaceutical and branded generic products from<br \/>\n      Merck, Crist\u00e1lia and Eurofarma solely in the Brazilian retail sector.\n    <\/p>\n<p>\n      &#8220;Merck is pleased to partner with two of Brazil\u2019s leading pharmaceutical<br \/>\n      companies &#8212; organizations that share our commitment to enhancing health<br \/>\n      care for the people of Brazil,\u201d said Kenneth C. Frazier, chairman and<br \/>\n      chief executive officer, Merck. &#8220;This venture is an important step<br \/>\n      forward in our strategy to grow our business in key markets and improve<br \/>\n      global access to our medicines and vaccines.&#8221;\n    <\/p>\n<p>\n      By establishing the JV with Supera, Merck will gain additional local<br \/>\n      expertise, an expanded portfolio of products and a strong distribution<br \/>\n      network to facilitate wider access to medicines for the people of<br \/>\n      Brazil. The initial portfolio of the JV will include approximately 30<br \/>\n      products across a range of therapeutic areas. The JV will have its own<br \/>\n      dedicated sales force separate from Merck, Crist\u00e1lia and Europharma, but<br \/>\n      will leverage the parent companies&#8217; infrastructures for activities such<br \/>\n      as sales force training. The parent companies will continue to maintain<br \/>\n      separate businesses in Brazil.\n    <\/p>\n<p>\n      Ogari Pacheco, president of Crist\u00e1lia, commented, &#8220;This joint venture is<br \/>\n      a combination of Cristali\u00e1\u2019s creativity, Eurofarma\u2019s commercial<br \/>\n      efficiency and Merck\u2019s innovation.\u201d\n    <\/p>\n<p>\n      Maurizio Billi, president of Eurofarma added, \u201cWe are sharing learnings<br \/>\n      and combining the very best of each company, making this joint venture<br \/>\n      more competitive in the Brazilian market. Partnering with Merck is a<br \/>\n      strategic move to advance access to innovative pharmaceutical products.&#8221;\n    <\/p>\n<p>\n      Merck, through a subsidiary, will own 51 percent of the JV, and<br \/>\n      Crist\u00e1lia and Eurofarma will collectively own 49. The venture will be<br \/>\n      managed by a joint board and leadership team consisting of members of<br \/>\n      senior management from the three companies. Establishment of the JV is<br \/>\n      subject to satisfying certain agreed upon closing conditions but is<br \/>\n      scheduled to be completed later in 2012.\n    <\/p>\n<p>\n      <b>About Crist\u00e1lia<\/b> <b>Labs<\/b>\n    <\/p>\n<p>\n      Crist\u00e1lia Labs (Crist\u00e1lia Produtos Quimicos Farmaceuticos Ltda.), a<br \/>\n      privately held Brazilian company founded in 1972, produces high quality<br \/>\n      medicines to address medical needs. Primarily focused on specialty areas<br \/>\n      such as psychiatry, anesthesia and pain relief, the company has become a<br \/>\n      healthcare leader across Latin America. Today, in addition to covering<br \/>\n      all territories within Brazil, Crist\u00e1lia exports reach approximately 40<br \/>\n      countries across Latin America, the Middle East, Asia and Africa.\n    <\/p>\n<p>\n      The company is a strong supporter of the Brazilian scientific community<br \/>\n      and a large number of universities within the country. The company also<br \/>\n      develops social responsibility and sustainability programs in the areas<br \/>\n      of education, the donation of medicines, and the offer of aid and<br \/>\n      assistance to poor communities. For more information, please visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.2cristalia.com.br&amp;esheet=50280480&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.2cristalia.com.br.&amp;index=1&amp;md5=7b527fa518c3cecdb02504e82b2087c8\"><span class=\"bwuline\">http:\/\/www.2cristalia.com.br<\/span>.<\/a>\n    <\/p>\n<p>\n      <b>About Eurofarma Laboratorios Ltda.<\/b>\n    <\/p>\n<p>\n      Established in 1972, Eurofarma ranks among the leading pharmaceutical<br \/>\n      companies in Brazil. The company operates in virtually all<br \/>\n      pharmaceutical segments through its Business Units \u2013 Prescription Drugs,<br \/>\n      Generics, Hospital &amp; Procurement, Oncology, Third-Party Services and<br \/>\n      Pearson (Veterinary). The company counts on the largest medical sales<br \/>\n      force in the country and performs about 380,000 sales calls per month.<br \/>\n      In 2010, for the seventh year in a row, the company ranked among the<br \/>\n      list of best companies to work for published by Exame\/ Voc\u00ea S\/A<br \/>\n      magazine. By 2015, it plans to have a strong international presence by<br \/>\n      covering 90% of the Latin-American market. The company\u2019s most recently<br \/>\n      developed manufacturing facility in Itapevi, Brazil aims to greatly<br \/>\n      increase the company\u2019s production capacity, making it an important<br \/>\n      production source for both the Brazilian and international markets. For<br \/>\n      more information, please visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.eurofarma.com.br&amp;esheet=50280480&amp;lan=en-US&amp;anchor=www.eurofarma.com.br.&amp;index=2&amp;md5=c6c8a9acf1d516d76b729260899a1e58\"><span class=\"bwuline\">www.eurofarma.com.br<\/span>.<\/a>\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies, and<br \/>\n      consumer care and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      healthcare through far-reaching policies, programs and partnerships. For<br \/>\n      more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=50280480&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=3&amp;md5=5a478449483cf9b55d918fab63d00d58\"><span class=\"bwuline\">vip2-msd.com\/merckcom-migrated<\/span><\/a><br \/>\n      and connect with us on Twitter, Facebook and YouTube.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. Such statements may include,<br \/>\n      but are not limited to, statements about the benefits of the merger<br \/>\n      between Merck and Schering-Plough, including future financial and<br \/>\n      operating results, the combined company\u2019s plans, objectives,<br \/>\n      expectations and intentions and other statements that are not historical<br \/>\n      facts. Such statements are based upon the current beliefs and<br \/>\n      expectations of Merck\u2019s management and are subject to significant risks<br \/>\n      and uncertainties. Actual results may differ from those set forth in the<br \/>\n      forward-looking statements.\n    <\/p>\n<p>\n      The following factors, among others, could cause actual results to<br \/>\n      differ from those set forth in the forward-looking statements: the<br \/>\n      possibility that the expected synergies from the merger of Merck and<br \/>\n      Schering-Plough will not be realized, or will not be realized within the<br \/>\n      expected time period; the impact of pharmaceutical industry regulation<br \/>\n      and healthcare legislation; the risk that the businesses will not be<br \/>\n      integrated successfully; disruption from the merger making it more<br \/>\n      difficult to maintain business and operational relationships; Merck\u2019s<br \/>\n      ability to accurately predict future market conditions; dependence on<br \/>\n      the effectiveness of Merck\u2019s patents and other protections for<br \/>\n      innovative products; the risk of new and changing regulation and health<br \/>\n      policies in the United States and internationally and the exposure to<br \/>\n      litigation and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2010 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=50280480&amp;lan=en-US&amp;anchor=www.sec.gov%29.&amp;index=4&amp;md5=3dd58916532f587c58f32e83b741d2f6\"><span class=\"bwuline\">www.sec.gov<\/span>).<\/a>\n    <\/p>\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20120516006266r1&amp;sid=sfsite1&amp;distro=nx\"><span class=\"bwct31415\"><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Kelley Dougherty, 908-423-4291<br \/>or<br \/>Investors:<br \/>Carol        Ferguson, 908-423-4465     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>New Brazilian Joint Venture to Combine Local and Global Commercial Expertise Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the formation of a new joint venture (JV) with Supera Farma Laboratorios S.A., a Brazilian pharmaceutical company co-owned by Crist\u00e1lia and Eurofarma. The new JV will market, distribute and sell a portfolio of innovative pharmaceutical and branded generic products from Merck, Crist\u00e1lia and Eurofarma solely in the Brazilian retail sector. &#8220;Merck is pleased to partner with two of Brazil\u2019s leading pharmaceutical companies &#8211; organizations that share our commitment to enhancing health care for the people of Brazil,\u201d said Kenneth C. Frazier, chairman and chief executive officer, Merck. &#8220;This venture is an important step forward in our strategy to grow our business in key markets and improve global access to our medicines and vaccines.&#8221; By establishing the JV with Supera, Merck will gain additional local expertise, an expanded<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,289],"class_list":["post-742248","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Establishes Joint Venture with Supera Farma to Commercialize Innovative Pharmaceutical Products and Branded Generics in Brazil - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-establishes-joint-venture-with-supera-farma-to-commercialize-innovative-pharmaceutical-products-and-branded-generics-in-brazil\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Establishes Joint Venture with Supera Farma to Commercialize Innovative Pharmaceutical Products and Branded Generics in Brazil - Merck.com\" \/>\n<meta property=\"og:description\" content=\"New Brazilian Joint Venture to Combine Local and Global Commercial Expertise Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the formation of a new joint venture (JV) with Supera Farma Laboratorios S.A., a Brazilian pharmaceutical company co-owned by Crist\u00e1lia and Eurofarma. The new JV will market, distribute and sell a portfolio of innovative pharmaceutical and branded generic products from Merck, Crist\u00e1lia and Eurofarma solely in the Brazilian retail sector. &quot;Merck is pleased to partner with two of Brazil\u2019s leading pharmaceutical companies - organizations that share our commitment to enhancing health care for the people of Brazil,\u201d said Kenneth C. Frazier, chairman and chief executive officer, Merck. &quot;This venture is an important step forward in our strategy to grow our business in key markets and improve global access to our medicines and vaccines.&quot; By establishing the JV with Supera, Merck will gain additional local expertise, an expanded\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-establishes-joint-venture-with-supera-farma-to-commercialize-innovative-pharmaceutical-products-and-branded-generics-in-brazil\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-22T04:04:25+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20120516006266r1&amp;sid=sfsite1&amp;distro=nx\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-establishes-joint-venture-with-supera-farma-to-commercialize-innovative-pharmaceutical-products-and-branded-generics-in-brazil\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-establishes-joint-venture-with-supera-farma-to-commercialize-innovative-pharmaceutical-products-and-branded-generics-in-brazil\\\/\",\"name\":\"Merck Establishes Joint Venture with Supera Farma to Commercialize Innovative Pharmaceutical Products and Branded Generics in Brazil - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-establishes-joint-venture-with-supera-farma-to-commercialize-innovative-pharmaceutical-products-and-branded-generics-in-brazil\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-establishes-joint-venture-with-supera-farma-to-commercialize-innovative-pharmaceutical-products-and-branded-generics-in-brazil\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20120516006266r1&amp;sid=sfsite1&amp;distro=nx\",\"datePublished\":\"2012-02-15T07:00:00+00:00\",\"dateModified\":\"2023-03-22T04:04:25+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-establishes-joint-venture-with-supera-farma-to-commercialize-innovative-pharmaceutical-products-and-branded-generics-in-brazil\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-establishes-joint-venture-with-supera-farma-to-commercialize-innovative-pharmaceutical-products-and-branded-generics-in-brazil\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-establishes-joint-venture-with-supera-farma-to-commercialize-innovative-pharmaceutical-products-and-branded-generics-in-brazil\\\/#primaryimage\",\"url\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20120516006266r1&amp;sid=sfsite1&amp;distro=nx\",\"contentUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20120516006266r1&amp;sid=sfsite1&amp;distro=nx\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-establishes-joint-venture-with-supera-farma-to-commercialize-innovative-pharmaceutical-products-and-branded-generics-in-brazil\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Establishes Joint Venture with Supera Farma to Commercialize Innovative Pharmaceutical Products and Branded Generics in Brazil\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Establishes Joint Venture with Supera Farma to Commercialize Innovative Pharmaceutical Products and Branded Generics in Brazil - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-establishes-joint-venture-with-supera-farma-to-commercialize-innovative-pharmaceutical-products-and-branded-generics-in-brazil\/","og_locale":"en_US","og_type":"article","og_title":"Merck Establishes Joint Venture with Supera Farma to Commercialize Innovative Pharmaceutical Products and Branded Generics in Brazil - Merck.com","og_description":"New Brazilian Joint Venture to Combine Local and Global Commercial Expertise Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the formation of a new joint venture (JV) with Supera Farma Laboratorios S.A., a Brazilian pharmaceutical company co-owned by Crist\u00e1lia and Eurofarma. The new JV will market, distribute and sell a portfolio of innovative pharmaceutical and branded generic products from Merck, Crist\u00e1lia and Eurofarma solely in the Brazilian retail sector. \"Merck is pleased to partner with two of Brazil\u2019s leading pharmaceutical companies - organizations that share our commitment to enhancing health care for the people of Brazil,\u201d said Kenneth C. Frazier, chairman and chief executive officer, Merck. \"This venture is an important step forward in our strategy to grow our business in key markets and improve global access to our medicines and vaccines.\" By establishing the JV with Supera, Merck will gain additional local expertise, an expanded","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-establishes-joint-venture-with-supera-farma-to-commercialize-innovative-pharmaceutical-products-and-branded-generics-in-brazil\/","og_site_name":"Merck.com","article_modified_time":"2023-03-22T04:04:25+00:00","og_image":[{"url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20120516006266r1&amp;sid=sfsite1&amp;distro=nx","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-establishes-joint-venture-with-supera-farma-to-commercialize-innovative-pharmaceutical-products-and-branded-generics-in-brazil\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-establishes-joint-venture-with-supera-farma-to-commercialize-innovative-pharmaceutical-products-and-branded-generics-in-brazil\/","name":"Merck Establishes Joint Venture with Supera Farma to Commercialize Innovative Pharmaceutical Products and Branded Generics in Brazil - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-establishes-joint-venture-with-supera-farma-to-commercialize-innovative-pharmaceutical-products-and-branded-generics-in-brazil\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-establishes-joint-venture-with-supera-farma-to-commercialize-innovative-pharmaceutical-products-and-branded-generics-in-brazil\/#primaryimage"},"thumbnailUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20120516006266r1&amp;sid=sfsite1&amp;distro=nx","datePublished":"2012-02-15T07:00:00+00:00","dateModified":"2023-03-22T04:04:25+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-establishes-joint-venture-with-supera-farma-to-commercialize-innovative-pharmaceutical-products-and-branded-generics-in-brazil\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-establishes-joint-venture-with-supera-farma-to-commercialize-innovative-pharmaceutical-products-and-branded-generics-in-brazil\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-establishes-joint-venture-with-supera-farma-to-commercialize-innovative-pharmaceutical-products-and-branded-generics-in-brazil\/#primaryimage","url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20120516006266r1&amp;sid=sfsite1&amp;distro=nx","contentUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20120516006266r1&amp;sid=sfsite1&amp;distro=nx"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-establishes-joint-venture-with-supera-farma-to-commercialize-innovative-pharmaceutical-products-and-branded-generics-in-brazil\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Establishes Joint Venture with Supera Farma to Commercialize Innovative Pharmaceutical Products and Branded Generics in Brazil"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"a70536e4-d523-4bd6-b8cf-a129242a550d","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Merck-Establishes-Joint-Venture-with-Supera-Farma-to-Commercialize-Innovative-Pharmaceutical-Products-and-Branded-Generics-in-Brazil-2012.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742248","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742248\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=742248"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=742248"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}